Project ConnQuER Progress in Eliminating Hep C in Persons with HIV in Connecticut



(<u>Connecticut Quantification</u>, <u>Evaluation</u>, <u>&</u> <u>Response</u>: <u>HIV/HCV Elimination in Persons of Color</u>)

Getting to Zero through Quality Management: A 2019 Summit

Merceditas Villanueva, MD Yale University School of Medicine Sept. 18, 2019

Hartford, CT



Convection

Presentation Outline

- Review epidemiology of HIV/HCV
- Review goals of Project ConnQuER
- Review progress towards enhancing surveillance of HCV infection among PLWH
- Review preliminary data
 - Multi-site cascade of care
 - Study on use of DIS for HIV/HCV out of care
- Discuss next steps



Overall Project Goals

- Cure Hepatitis C (HCV) in persons living with HIV (PLWH) in CT, particularly persons of color through improvements in the HCV cascade of care
- 2. Improve partnerships with key stakeholders
- 3. Improve surveillance mechanisms statewide for HIV/HCV coinfection



Epidemiology



Estimated 70 Million Persons Living With HCV



Polaris Observatory HCV Collaborators. Lancet Gastroenterol Hepatol. 2017;2:161-176.

Slide credit: clinicaloptions.com

National HCV Statistics

3.5 million individuals



41,200 cases in 2016



Changing Epidemiology of HCV in the US



- Screening → linkage to HCV care → DAA treatment cascade must be operative in all those at risk
- Treatment of PWIDs plus harm reduction efforts essential part of elimination efforts

California Department of Public Health. Chronic hepatitis C infections in California: cases newly reported through 2015. June 2017.

Slide credit: <u>clinicaloptions.com</u>

25% have HIV/HCV co-infection



Persons living with HIV are Living Longer



ART Over Time



ART Simpler and Safer







Dovato

Molutegravic and Menivudine)

Tableta 50 mg/300 mg/

The Revolution of Direct Acting Antivirals (DAAs)

The Evolution of HCV Therapy



Slide credit: clinicaloptions.com

DAAs 2019 (Partial List)











Summary of Trends

- PLWH are living longer due to advances in HIV treatments
- Persons with HIV/HCV coinfection have increased morbidity and mortality from liver disease
- New HCV treatments with direct acting agents (DAAs) are highly effective
- There are multiple barriers to achieving cure in HIV/HCV coinfected population



Looking at Cascades of Care





OUR GOAL

Getting to zero new infections requires...













HIV Continuum of Care: CT DPH

HIV Continuum of Care, Connecticut, 2017



WHO Hepatitis Elimination Goals

TOWARDS ELIMINATION OF VIRAL HEPATITIS BY 2030



BASELINE

2030 TARGETS FOR ELIMINATION





Major simplification and scale-up of hepatitis C treatment is now possible





Treatment Cascade for Chronic HCV: US Model (2014)





HCV Cascade in PLWH following HCV Diagnosis, UCSD Owen Clinic

Total number of patients with access to HIV care with HCV antibody positive (n=748)

Chronic active HCV infection with access to HIV care 100% (n=562)

Referred for HCV treatment 54% (n=303)

Attended at least 1 clinic visit for HCV treatment evaluation 50% (n=283)

Final decision made regarding HCV therapy initiation **44% (n=250)**

Initiated HCV treatment 16% (n=88)

> HCV cure **7% (n=41)**



Cachay, et al. Plos ONE 2014.

THERE IS NO AVAILABLE HCV CASCADE OF CARE FOR CONNECTICUT



PROJECT ConnQuER



HRSA 047 (Project ConnQuER)

- HRSA SPNS (Special Project of National Significance) project: 3-year project
- "Curing Hepatitis C Among People of Color Living with HIV"
- Two recipients:
 - University of TX, San Antonio
 - Yale University
- GOAL: Create a HCV cascade of care in PLWH in CT



Capacity Model: Barriers



Project Partners



DIS: disease intervention specialists SSP: syringe service programs AETC: AIDS Education & Training Center



Map of Connecticut Partners



Surveillance Improvements



Data Flow Model



Barriers to Hep C Surveillance in CT

- CT Statute (reportable labs)
 - All positive Antibodies
 - All RNA positive results
 - All genotype
 - All negative RNA results through Electronic Lab Reporting (ELR) only
- Lack of dedicated staff for manual data entry
- Incomplete ELR



HCV Paper Lab Backlog Efforts



- Update CTEDSS with backlog of paper labs from 2016-2018
- When this effort began in July 2018, there were roughly 20 of these banker boxes full of paper labs that needed to be looked up in the database and entered.



March 2019 (right before temps started)



May 2019





June 2019



Constructing the Data Flow Model



DPH HIV/HCV Data Matching Flowchart



HCV-HIV Matching Flowchart

Use SAS 9.4 (SAS Institute, Inc., Cary, North Carolina, USA). SAS extracts from CTEDSS and eHARS. Match using a CDC developed hierarchical deterministic matching SAS program. Method validated by 6 jurisdictions (findings published in American Journal of Epidemiology, kwy161,

*We created a Master List from all CTEDSS cases (HCV surveillance since 1994) matched to eHARS patients active from 2009-2018. This yielded an estimated 5185 patients Connecticut statewide **potentially co-infected** since 1994.



Multisite Clinics Cascade of Care Preliminary Results



Multi-Site Clinics: Preliminary Results of Surveillance Matching



- Cohort: Patients with HIV-related medical services, then matched to positive HCV screening results
- *Timeframe:* 1/2009-12/2018
- *Participating partners:* 11 clinics



Multi-Site Clinics: 11 Clinics to Date Preliminary Results of Surveillance Matching

Coinfected Patient Demographics (eHARS) Gender:

- 68% Male
- 32% Female

Race/Ethnicity:

- 34% Black
- 28% Hispanic
- 24% White
- 1% Other
- 12% Not Reported

Reported HIV risk factor(s):

 75% IDU only; 7% MSM only; 4% MSM/IDU; 11% Hetero; 3% Other

Age:

- Median 60 yo (IQR: 54-64 yo)
- Minimum 23 yo, Maximum 88 yo

Total Number
ofUnique
patients
n=1496


CTEDSS Match Findings in Multi-Site Clinics







Preliminary HIV/HCV Broad Outcomes

11 clinics, 2009-2018, (n=1496)



Preliminary HIV/HCV Detailed Outcomes 11 clinics, 2009-2018, (n=1496): Treatment Eligible



HCV Treatment Cascade Baseline for Multi-site Clinics



Local Evaluation Plan: Looking at HIV/HCV Persons who are out of care?



Efficacy of Using Disease Intervention Specialist (DIS) to Re-engage Out of Care HIV/HCV Co-infected Persons in HCV Treatment





Using Surveillance Data to Determine HCV Outcomes (Rules for Determining if a Patient has SVR, Self-Cleared, or a False Positive)

HCV Antibody	HCV PCR	Interpretation	
	None reported	Incomplete evaluation	
	Negative on same date/specimen	Spontaneous clearance	
	Positive on same date/specimen <u>followed by</u> 2 or more positive PCRs	Chronically infected, untreated	
Positive	Positive on same date/specimen <u>followed by</u> negative PCR >4 weeks but <20 weeks later	Chronically infected, undergoing treatment	
	Positive on same date/specimen <u>followed by t</u> wo or more negative PCRs with different collection dates	Chronically infected, SVR	
	Positive on same date/specimen <u>followed by</u> negative PCR >20 weeks later	Chronically infected, SVR	
	Positive on same date/specimen <u>followed</u> <u>by</u> negative PCR >20 weeks later <u>followed</u> by positive PCR with same or different genotype	Chronically infected, reinfection after SVR	
Negative or Positive	Quantitative negative <u>with</u> qualitative positive on same date/specimen	Error or false positive	
Negative	N/A	Reporting error 43	

Connecticut: HIV/HCV OOC (18 months)









Hartford County: HIV/HCV OOC (18 months)







New Haven County: HIV/HCV OOC (18 months)



Fairfield County: HIV/HCV OOC (18 months)







Role of Case Conference

- Will inform on details not available through surveillance alone
- Team:
 - DIS
 - DPH (Deb Gosselin)
 - Individual clinic staff
- Tweak OOC model: 18 months? 12 months?





Next Steps



Advancing Use of Data to Care

- Applying surveillance data to estimate the cascade of care in CT:
 - All HIV/HCV
 - Mono-infected
- Deeper dive into persons who have not been treated
 - Persons who are coming to clinic but not being treated for HCV
 - Persons who are not coming to clinic and/or moving from clinic to clinic
- What service delivery innovations can we use to improve the cascade of care?





Advancing Data to Care as a Prevention Strategy to Reduce HIV Morbidity and Mortality in the U.S.

Coordinating Editors: Antrew D. Margola, R. Late Shouse, Blistleth A. Officero.

- HV Data to Care Oping Public Health Data to triprive HV Care and Prevention
- Informing Gata to Gare Contacting Persons Sampled for the Stadical Maximum Project
- Improving NV Surveillance Data by Using the Allis Black Bio Sentent to Assist Regional Deduction Activities
- Easts to Care Opportunities: An Evaluation of Persons Living Web HM Reported to be "Current to Ease" Without Current HM Adapted Labs
- Evaluating XN Sover-Farce Complements Along the Continuum of Care. Segmenting Sarverlance Web. Health Canter Delor is thetrane NY Carla to Care. Efficiency
- Early IV Saverilarco and Circle Data to Deterior Data to Care Efforts in Community Hearth Content in Messachusetts The Manachusetts Partnerships for Care Preset

- Occu-Jurisdictional Data to Care Lasouris Learned in New York Data and Provida
- The Permerchips for Care Project is Vacuationets: Developing Permerchips and Data Testams to Increase Unitage and Engagement in Care for Individual Uning Wate InV
- Promoting Data as an Alternative Data Science of Implementation of a Data to Care Strategy
- Implementing Data to Care—What Are the Carls for the Heads
- Stori Tem Outcomes and Lessons Loomed Free the Federal HGI Health Improvement Athing Soughts State Vedical/Orlaber's Health Insurance Program Agencies Not State Health Departments
- Operational Units a Della In Della Strategy in Michigan Privage Deals Agency Californiations
- Data to Gete Losains Loaned Fran Delivering Technical Assistance to 20 Hoalth Departments

💌 Wolters Kluwer



OVID



Acknowledgements



CT Dept of Public Health Heidi Jenkins Suzanne Speers Linda Ferraro Deb Gosselin

Disease Intervention Specialists:

Venesha Heron (Hartford) Emily Hartwell (Norwalk) Reina Cordero (New Haven)

Renta cordero (New Haven)				
		Program Name	County	
	rograms	Community Health Care Van	New Haven	
<u>SSPs/SUDs</u>	rvice Pr	Greater Bridgeport Area Prevention Program	Fairfield	
	Syringe Service Programs	AIDS CT (ACT)	Hartford	
	se Disorder Clinics	APT Foundation	New Haven	
		Recovery Network of Programs	Fairfield	
	Substance Use	Wheeler Clinic	Hartford	

Multi-site Clinics





Yale Team







Ditas Villanueva Principal Investigator

Rick Altice Principal Investigator



David Vlahov **Principal Investigator**



Lisa Nichols **Project Manager**



Bob Sideleau AETC Director



Ralph Brooks

Data Manager



Max Wegener Epidemiologist



Statistician





Janet Miceli **Christina Rizk CareWare Coordinator** Tequetta Valeriano Research Assistant



